Skip to main content
. Author manuscript; available in PMC: 2023 Jan 10.
Published in final edited form as: Cancer Cell. 2021 Dec 30;40(1):53–69.e9. doi: 10.1016/j.ccell.2021.12.005

Figure 2. Antigen density of candidate immunotherapy targets on clinical samples of NB cells metastatic to the bone marrow.

Figure 2.

A) Gene expression of GPC2 and ANPEP (CD13) in a panel of NB cell lines (dataset: GSE89413)

B) Flow cytometric cell surface expression of CD13 on negative CTRL cells (CHO), NB cell lines and HS-5 BM stroma cells.

C) Representative CD45-CD13- and NCAM+GD2+ gating strategy to identify NB tumor cell populations in clinical BM samples.

D) Cell surface antigen quantification (molecules/cell) of GPC2, NCAM, GD2, L1CAM, ALK and B7-H3 on BM infiltrating NB cells (BM_TU), Cell Lines (CL) and patient derived xenograft tumors (PDX) assessed by multicolor flow cytometry antigen density quantification assay. Horizontal lines indicate median. Statistics represent Welch’s t-test (**** = p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05), ns = p > 0.05). Statistical parameters of the samples are shown in Figure S3B.

See also Figure S3.